Hemodynamic effects of succinate-containing dialyzing solution


Cite item

Full Text

Abstract

Aim. To assess the results of using an acetate-free succinate-containing dialyzing solution (SDS) against natremia and blood pressure (BP) in patients on chronic hemodialysis (HD). Subjects and methods. Ninety-two patients were transferred from 3 Saint Petersburg HD centers to 3-month HD treatment using SDS. The investigators measured blood biochemical indicators immediately before and 1 and 3 months after the investigation, BP before and after a successive HD session, and the patients’ weight and its gain in the period between HD sessions. Hypotensive and hypertensive episodes were recorded during HD sessions throughout the investigation. Results. Following 3-month treatment using SDS, there were statistically significant decreases in blood sodium levels and systolic BP (SBP) prior to a HD session. At the same time, patients with a baseline pre-HD SBP of less than 100 mm Hg were observed to have a statistically significant increase in this indicator by the end of the investigation. Pre-dialysis diastolic BP (DBP) and post-dialysis SBP and DBP substantially unchanged. After 3 months of SDS use, there was a statistically significant reduction in weight gain in the period between HD sessions. When SDS was administered, the frequency of hypertensive episodes tended to decline after a HD session. Conclusion. The use of SDS causes a drop in pre-dialysis blood sodium levels, ensuring adequate dehydration in patients and improving hypertension control. In doing so, SDS prevents hypotension during a HD session.

References

  1. Charra B. Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int. 2007;11(1):21-31.
  2. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1-S153.
  3. Jablonski KL, Chonchol M. Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease. F1000 Prime Reports. 2014;6:2. doi: 10.12703/p6-72.
  4. Rahman M, Dixit A, Donley V, Gupta S, Hanslik T, Lacson E, Ogundipe A, Weigel K, Smith MC. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis. 1999;33(3):498-506.
  5. Horl MP, Horl WH. Hemodialusis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis. 2002;39(2): 227-244.
  6. Xavier PS, Vogt BP, Martin LC, Vaninni F, Antunes AA, Ponce D, Caramori JCT, dos Santos e Silva Martin R, da Silva Franco RJ, Barretti P. Total body water and failure to control blood pressure by medication in hemodialysis patiehts. Nephron Extra. 2014;4(2):95-100. doi: 10.1159/000363322.
  7. Scribner BH, Burl R, Caner JE, Hegstrom R, Burnell JM. The treatment of cronic uremia by means of intermittent hemodialysis: a preliminary report. Trans Am Soc Artif Intern Organs. 1960;6: 114-122.
  8. Hecking M, Karaboyas A, Antlanger M, Saran R, Wizemann V, Chazot C, Rayner H, Hörl WH, Pisoni RL, Robinson BM, Sunder-Plassmann G, Moissl U, Kotanko P, Levin NW, Säemann MD, Kalantar-Zadeh K, Port FK, Wabel P. Significance of interdialytic weight gain versus chronic volume overload: consensus opinion. Am J Nephrol. 2013;38(1):78-90. doi: 10.1159/000353104.
  9. Ozkahya M, Ok E, Toz H, Asci G, Duman S, Basci A, Kose T, Dorhout Mees EJ. Long-term survival rates in haemodialysis patients treated with strict volume control. Nephrol Dial Transplant. 2006;21(12):3506-3513.
  10. Keen ML, Gotch FA. The association of the sodium «setpoint» to interdialytic weight gain and blood pressure in hemodialysis patients. Int J Artif Organs. 2007;30(11):971-979.
  11. Peixoto AJ, Gowda N, Parikh CR, Santos SF. Long-term stability of serum sodium in hemodialysis patients. Blood Purif. 2010;29(3):264-267. doi: 10.1159/000274460.
  12. Регистрационное удостоверение №ФСР 2009/04126 от 6 февраля 2009 г., срок действия не ограничен.
  13. Cмирнов А.В., Нестерова О.Б., Голубев Р.В., Коростелева Н.Ю., Дегтерева О.А., Боровская Е.А., Галкина О.В., Васильев А.Н., Вербицкая Е.В., Старосельский К.Г., Лазеба В.А. Кардиопротективные эффекты сукцинатсодержащего диализирующего раствора. Нефрология. 2012;16(2):69-78.
  14. Смирнов А.В., Нестерова О.Б., Суглобова Е.Д., Голубев Р.В., Васильев А.Н., Васильева И.А., Вербицкая Е.В., Коростелева Н.Ю., Костерева Е.М., Лебедева Э.Б., Левыкина Е.Н., Старосельский К.Г., Лазеба В.А. Клинико-лабораторная оценка эффективности лечения больных с терминальной стадией почечной недостаточности с использованием хронического гемодиализа и ацидосукцината. Терапевтический архив. 2013;85(1):69-75.
  15. Васильева И.А. Российская версия опросника Kidney Disease Quality of Life Short Form (KDQOL-SF) — ценного диагностического инструмента для оценки качества жизни больных на диализе. Нефрология. 2007;11(1):64-70.
  16. Васильева И.А., Добронравов В.А., Панина И.Ю. Качество жизни больных на различных стадиях хронической болезни почек. Нефрология. 2013;17(2):60-66.
  17. Смирнов А.В., Васильева И.А., Нестерова О.Б., Голубев Р.В., Васильев А.Н., Коростелева Н.Ю., Старосельский К.Г. Качество жизни и когнитивные функции у пациентов с терминальной стадией почечной недостаточности, получающих гемодиализ с использованием сукцинатсодержащего диализирующего раствора. Терапевтический архив. 2014;86(6): 11-17.
  18. Регистрационное удостоверение №ФСР 2011/12767 от 28 декабря 2011 г., срок действия не ограничен.
  19. Lambie SH, Taal MW, Fluck RJ, McIntyre CW. Online conductivity monitoring: validation and usefulness in a clinical trial of reduced dialysate conductivity. ASAIO J. 2005;51(1):70-76.
  20. Santos SFF, Peixoto AJ. Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(2):522-530. doi: 10.2215/cjn.03360807.
  21. Flanigan MJ. Role of sodium in hemodialysis. Kidney Int. 2000;58(Suppl.76):S72-S78.
  22. Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int. 2008;73(6):759-764.
  23. Шляхто Е.В., Галагудза М.М., Нифонтов Е.М., Евтерева Е.Д. Метаболизм миокарда при хронической сердечной недостаточности и современные возможности метаболической терапии. Сердечная недостаточность. 2005;4:148-155.
  24. Смирнов А.В., Нестерова О.Б., Голубев Р.В. Янтарная кислота и ее применение в медицине. Часть I. Янтарная кислота: метаболит и регулятор метаболизма организма человека. Нефрология. 2014;18(2):33-41.
  25. Смирнов А.В., Нестерова О.Б., Голубев Р.В. Янтарная кислота и ее применение в медицине. Часть II. Применение янтарной кислоты в медицине. Нефрология. 2014;18(4):12-24.
  26. Vargas SL, Toma I, Kahg JJ, Meer EJ, Peti-Peterdi J. Activation of the succinate receptor GPR91 in macula densa cells causes renin release. J Am Soc Nephrol. 2009;20(5):1002-1011. doi: 10.1681/asn.2008070740.
  27. Deen PMT, Robben JH. Succinate receptors in the kidney. J Am Soc Nephrol. 2011;22(8):1416-1422. doi: 10.1681/asn.2010050481.
  28. Pluznic JL. Renal and cardiovascular sensory receptors and blood pressure regulation. Am J Physiol Renal Physiol. 2013;305(4):F439-F444. doi: 10.1152/ajprenal.00252.2013.
  29. Sundstrom L, Greasley PJ, Engberg S, Wallander M, Ryberg E. Succinate receptor GPR91, a Gai coupled receptor that increases intracellular calcium concentrations through PLCb. FEBS Lett. 2013;587(15):2399-2404.
  30. Titze J, Machnic A. Sodium sensing in the interstitium and relationship to hypertension. Curr Opin Nephrol Hypertens. 2010;19(4): 385-392. doi: 10.1097/mnh.0b013e32833aeb3b.
  31. Titze J, Dahlmann A, Lerchl K. Kopp C, Rakova N, Schröder A, Luft FC. Spooky sodium balance. Kidney Int. 2013;85(4):759-767. doi: 10.1038/ki.2013.367.
  32. Titze J, Muller DN, Luft FC. Taking another «look» at sodium. Can J Cardiol. 2014;30(5):473-475. doi: 10.1016/j.cjca.2014.02.006.
  33. Jantsch J, Binger KJ, Muller DN, Titze J. Macrophages in homeostasis immune function. Front Physiol. 2014;5:146. doi: 10.3389/fphys.2014.00146.
  34. Wiig H, Schroder A, Neuhofer W, Jantsch J, Kopp C, Karlsen TV, Boschmann M, Goss J, Bry M, Rakova N, Dahlmann A, Brenner S, Tenstad O, Nurmi H, Mervaala E, Wagner H, Beck FX, Müller DN, Kerjaschki D, Luft FC, Harrison DG, Alitalo K, Titze J. Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest. 2013;123(7):2803-2815. doi: 10.1172/jci60113.
  35. Sapieha P, Sirinyan M, Hamel D, Zaniolo K, Joyal JS, Cho JH, Honoré JC, Kermorvant-Duchemin E, Varma DR, Tremblay S, Leduc M, Rihakova L, Hardy P, Klein WH, Mu X, Mamer O, Lachapelle P, Di Polo A, Beauséjour C, Andelfinger G, Mitchell G, Sennlaub F, Chemtob S. The succinate receptor GPR 91 in neurons has a major role in retinal angiogenesis. Nat Med. 2008;14(10):1067-1076. doi: 10.1038/nm.1873.
  36. Taylor CT. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J. 2008;409(1):19-26. doi: 10.1038/nm.1873.
  37. Ariza AC, Deen PMT, Robben JH. The succinate receptor as a novel therapeutic target for oxidative and metabolic stress-related conditions. Front Endocrinol. 2012;3(22):1-8. doi: 10.3389/fendo.2012.00022.
  38. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg. 1995;21(2):314-324.
  39. Lee SW. Sodium balance in maintenance hemodialysis. Electrolyte Blood Press. 2012;10(1):1-6. doi: 10.5049/ebp.2012.10.1.1.
  40. Yang S, Fang S, Jing L, Ma L, Huang J, Zhou Y, Liu W. Effects of mildly increasing dialysis sodium removal on renin and sympathetic system in hemodialysis patients. Chin Med J. 2014;127(14):2628-2631.
  41. Hakak Y, Lehmann-Bruinsma K, Phillips S, Le T, Liaw C, Connolly DT, Behan DP. The role of the GPR91 ligand succinate in hematopoiesis. J Leucoc Biol. 2009;85(5):837-843. doi: 10.1189/jlb.1008618.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies